Anthracyclines for HER2-Positive Early Breast Cancer

Oncology beyond the Obvious Webinar Series 21Подробнее

Lightning Updates | 2023 Best of Breast ConferenceПодробнее

HR+ Invasive Lobular Carcinoma Management - OncBrothers (Rohit & Rahul Gosain) w/ Dr. Jason MouabbiПодробнее

Leveraging Targeted Therapies to Improve Outcomes Across the Continuum of HER2+ Breast CancerПодробнее

Cardio-oncology: Chemotherapy-related left ventricular dysfunctionПодробнее

Advances in Breast Cancer: Adjuvant Therapy Escalation and De-escalation: What is the future?Подробнее

Breast Cancer Management in North Carolina: Updates for 2021 - Y. Abdou - 20210623Подробнее

Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBCПодробнее

Systemic therapy in operable HER2 positive breast cancerПодробнее

2022 West Oncology Conference | Breast Cancers | Early-StageПодробнее

HER2+ Early-Stage Breast Cancer: Peri-Operative TherapyПодробнее

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer TreatmentПодробнее

Dr. Julie R. Gralow on HER2-Positive Early Breast CancerПодробнее

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of BenefitПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Dr. Blum on Takeaways from ABC Trials for Breast CancerПодробнее

Update from KAITLIN for high-risk HER2-positive early breast cancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Neelima Denduluri, MD -- Treatment of Triple Negative Breast CancerПодробнее

Adjuvant Therapy for Early-Stage HER2-Positive Breast CancerПодробнее